ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

Share this content:
ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA
ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

WEDNESDAY, Sept. 28, 2016 (HealthDay News) -- For women with cervical and endometrial cancer, treatment with intensity-modulated radiation therapy (IMRT) is associated with reduced toxicity, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 25 to 28 in Boston.

Ann H. Klopp, M.D., Ph.D., from the MD Anderson Cancer Center in Houston, and colleagues stratified patients with cervical and endometrial cancer who received pelvic radiation postoperatively by dose, use of chemotherapy, and disease site. Two hundred seventy-eight patients were randomized to standard four-field radiation or IMRT.

The researchers found that the decline in the Expanded Prostate Cancer Index Composite bowel summary score at five weeks was significantly larger for the conventional RT arm versus the IMRT arm (P = 0.048). The median change in bowel function subscale was −17.9 and −14.3 for the conventional RT and IMRT arms, respectively. More high-level adverse events were experienced by patients in the conventional arm at five weeks from the start of RT.

"Many radiation oncologists already use IMRT for women undergoing pelvic radiation, but this research provides data that using IMRT, which is a more resource intensive treatment, makes a real difference to patients receiving radiation therapy to the pelvic area," Klopp said in a statement. "When performed by an experienced radiation oncology team, IMRT reduces the risk of short-term bowel and bladder side effects for patients with endometrial and cervical cancer."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »